Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06010017 · ClinicalTrials.gov registry record · NA
Peer Support Intervention for Patients Undergoing Hematopoietic Stem Cell Transplantation
A NA study of Hematopoietic Malignancy and Hematopoietic Neoplasms, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- NA
- Development phase
- 136
- Enrollment target
- 2
- Study locations
NCT06010017 is a NA study of Hematopoietic Malignancy and Hematopoietic Neoplasms that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 136 participants. The trial reports 2 study locations across 1 state.
The verdict
NCT06010017, a NA study of Hematopoietic Malignancy and Hematopoietic Neoplasms, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 136 participants
- Enrollment target
- 2
- Study locations
Study Summary
The main purpose of this study is to determine if a novel peer support intervention (STEPP) is feasible among patients undergoing hematopoietic stem cell transplantation (HSCT). The name of the intervention used in this research study is STEPP, a peer support intervention comprised of five learning modules on psychoeducation and supportive psychotherapy strategies, tailored to the unique needs of patients undergoing HSCT.
Conditions Studied
Interventions
- BEHAVIORAL STEPP Intervention
Study Locations (2)
Massachusetts
- Dana-Farber Cancer Institute - Boston
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2024-02-20 |
| Est. Completion | 2025-03-21 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06010017
The ClinicalTrials.gov registry entry for NCT06010017 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 136 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Hematopoietic Malignancy appearing as the primary indexed condition, and to 1 intervention - of which STEPP Intervention is the first listed.
NCT06010017 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06010017 about?
NCT06010017 is a clinical study titled "Peer Support Intervention for Patients Undergoing Hematopoietic Stem Cell Transplantation". The main purpose of this study is to determine if a novel peer support intervention (STEPP) is feasible among patients undergoing hematopoietic stem cell transplantation (HSCT). The name of the intervention used in this research study is STEPP, a peer support intervention comprised of five learning...
What is the current status of trial NCT06010017?
This trial is currently completed. It is a NA study. The enrollment target is 136 participants. The study started on 2024-02-20. Estimated completion is 2025-03-21.
What conditions does trial NCT06010017 study?
This clinical trial studies the following conditions: Hematopoietic Malignancy, Hematopoietic Neoplasms.
What interventions are being tested in trial NCT06010017?
The interventions under investigation include: STEPP Intervention (BEHAVIORAL).
Who is sponsoring clinical trial NCT06010017?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06010017 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematopoietic Malignancy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.